BREZTRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

FOR PATIENTS WITH COPD,
CHOOSE BREZTRI1-3

BREZTRI is not indicated for the relief of acute bronchospasm or for the treatment of asthma.

BREZTRI significantly reduced the annual rate of moderate or severe COPD exacerbations vs LAMA/LABA (RR=0.76; 95% CI: 0.69, 0.83; P<0.0001) and ICS/LABA (RR=0.87; 95% CI: 0.79, 0.95; P=0.0027) in a 52-week study.1†‡ Annual rate estimate: BREZTRI 1.08; LAMA/LABA 1.42; ICS/LABA 1.24.1

In a 52-week study in patients with ≥1 exacerbation within the last year,

THE ONLY TRIPLE THERAPY§ VS ICS/LABA TO SHOW A SIGNIFICANT REDUCTION IN COPD HOSPITALIZATIONS2,4,5*

*Hospitalization for a severe COPD exacerbation.

20% Reduction in COPD Hospitalization
20% Reduction in COPD Hospitalization

REDUCTION VS ICS/LABA2,4

(rate ratio=0.80; 95% CI: 0.66, 0.97; P=0.02)

STUDY 1

Reduction in severe exacerbations2‡

16% reduction vs LAMA/LABA (rate ratio=0.84; 95% CI: 0.69, 1.03; P=0.09)2

Annual rate estimate: BREZTRI 0.13 (n=2137); ICS/LABA 0.16 (n=2131); LAMA/LABA 0.15 (n=2120).2

Significant reduction in moderate or severe exacerbations

24% reduction vs LAMA/LABA (rate ratio=0.76; 95% CI: 0.69, 0.83; P<0.0001)

13% reduction vs ICS/LABA (rate ratio=0.87; 95% CI: 0.79, 0.95; P=0.0027)

Annual rate estimate: BREZTRI 1.08 (n=2137); LAMA/LABA 1.42 (n=2120); ICS/LABA 1.24 (n=2131).

Study 1: Patients (N=8588) with ≥1 moderate or severe exacerbation(s) in the year prior to screening.

BREZTRI is administered as 2 inhalations twice daily.

Moderate exacerbations were defined as those leading to treatment with systemic corticosteroids and/or antibiotics, and severe exacerbations were defined as those resulting in hospitalization or death.

§Fixed-dose combination: ICS/LAMA/LABA.

ǁBased on predefined Type-1 error control plan.

RR=rate ratio.

BREZTRI demonstrated a significant improvement in FEV1 AUC0-4 vs ICS/LABA (116 mL; P<0.0001) and an improvement in mean change from baseline in morning pre-dose trough FEV1 vs LAMA/LABA (13 mL; P=0.2375) in a 24-week study.1,3

In a 24-week study where the majority of patients did not have a history of exacerbations within the last year,6*

THE ONLY TRIPLE THERAPY VS LAMA/LABA TO PREVENT MODERATE OR SEVERE EXACERBATIONS1,3,5‡

52% Reduction in Exacerbation
52% Reduction in Exacerbation

REDUCTION VS LAMA/LABA1,3

(rate ratio=0.48; 95% CI: 0.37, 0.64; unadjusted P<0.0001)1,3§

STUDY 2

Reduction in moderate or severe exacerbations1,3‡

18% reduction vs ICS/LABA (rate ratio=0.82; 95% CI: 0.58, 1.17; P=0.2792)1,3

Annual rate estimate: BREZTRI 0.46 (n=639); ICS/LABA 0.56 (n=314); LAMA/LABA 0.95 (n=625).3

Difference in severe exacerbationsǁ (other endpoint)7‡

BREZTRI vs LAMA/LABA (rate ratio=0.36; 95% CI: 0.18, 0.70)

BREZTRI vs ICS/LABA (rate ratio=0.85; 95% CI: 0.34, 2.13)

Annual rate estimate: BREZTRI 0.05 (n=639); ICS/LABA 0.05 (n=314); LAMA/LABA 0.13 (n=625).

*Study 2: Patients (N=1896) were not required to have a history of moderate or severe exacerbations in the year prior to screening.

BREZTRI is administered as 2 inhalations twice daily.

Fixed-dose combination: ICS/LAMA/LABA.

Moderate exacerbations were defined as those leading to treatment with systemic corticosteroids and/or antibiotics, and severe exacerbations were defined as those resulting in hospitalization or death.

§P value is considered unadjusted due to nonsignificant results higher in the testing hierarchy.

ǁResults are descriptive only.

BREZTRI IS THE ONLY TRIPLE THERAPY* THAT CONTAINS BUDESONIDE1,5

*Fixed-dose combination: ICS/LAMA/LABA.